Company Profile
Lenz Therapeutics Inc Stock Price, News & Analysis
- Ticker:
- LENZ
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.22 USD (-0.95%)
Close
Last updated: August 6, 2026
224M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, LENZ closed down 0.95% at $5.22. No new same-company headline was identified in the current news window.
Company overview
Presbyopia-Focused Company
LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision.
VIZZ
VIZZ is an aceclidine ophthalmic solution designed to improve near vision through pupil modulation while limiting accommodative stimulation. It is the company's principal commercial product and the foundation of its presbyopia franchise. LENZ markets VIZZ through eye-care professionals while also building consumer awareness through direct-to-consumer outreach. Its strategy depends on prescription generation, patient trial and repeat use in a newly developing treatment category.
Future catalysts
LENZ’s catalysts are cataract / ophthalmology platform updates and any commercialization or clinical step that clarifies the company’s path. The market will care about whether the eye-care story keeps building.
Recent news
- 01
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
Source: Lenz Therapeutics Inc
- 02
- 03
- 04
- 05
LENZ Therapeutics to Participate in Upcoming Investor Conferences
Source: Lenz Therapeutics Inc
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lenz Therapeutics Inc (LENZ)?
Lenz Therapeutics Inc (LENZ) most recently closed at 5.22 USD, a -0.95% move versus the previous session.
What is the market cap of Lenz Therapeutics Inc (LENZ)?
Lenz Therapeutics Inc currently has a market capitalization of 224M USD on BioPharmSignal.
What does Lenz Therapeutics Inc do?
Presbyopia-Focused Company LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision. VIZZ VIZZ is an aceclidine ophthalmic solution designed to improve near vision through pupil modulation while limiting accommodative stimulation. It is the company's principal commercial...
On which exchange is LENZ stock listed?
Lenz Therapeutics Inc (LENZ) is associated with NASDAQ, United States, Biopharma.
What is Presbyopia-Focused?
Presbyopia-Focused Company LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision.
Which conditions is Lenz Therapeutics Inc targeting with Presbyopia-Focused?
Lenz Therapeutics Inc is associated with ophthalmology based on its company overview and current catalyst commentary.
How does Lenz Therapeutics Inc describe recent progress with Presbyopia-Focused?
LENZ’s catalysts are cataract / ophthalmology platform updates and any commercialization or clinical step that clarifies the company’s path. The market will care about whether the eye-care story keeps building.
What is Therapeutics?
Presbyopia-Focused Company LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision.